What is the recommended first‑line daratumumab‑based triplet regimen and its dosing for a patient with multiple myeloma?

Recommended First-Line Daratumumab-Based Triplet Regimen for Multiple Myeloma

For newly diagnosed multiple myeloma patients, daratumumab-lenalidomide-dexamethasone (DRd) is the preferred first-line daratumumab-based triplet regimen, with dosing of daratumumab 16 mg/kg IV weekly for weeks 1-8, every 2 weeks for weeks 9-24, then every 4 weeks thereafter; lenalidomide 25 mg orally days 1-21; and dexamethasone 40 mg orally weekly, all on 28-day cycles. 1

Rationale for DRd as Preferred Regimen

Multiple guidelines and recent evidence converge on DRd as the optimal daratumumab-based triplet:

• The 2020 Blood Cancer Journal guidelines explicitly state DRd as their preferred option based on producing the best reduction in risk of progression compared to lenalidomide-dexamethasone alone, combined with favorable tolerability 2

• The 2019 ASCO/CCO guidelines identify daratumumab-lenalidomide-dexamethasone as the best treatment option among 16 regimens analyzed, with the highest ranking and probability of being the best treatment for relapsed myeloma 3. While these data are from relapsed disease, the regimen's superiority translates to first-line use

• The 2025 NCCN Guidelines list daratumumab/lenalidomide/dexamethasone as a Category 1 preferred regimen for non-transplant candidates 4

• FDA approval supports this indication for newly diagnosed patients ineligible for autologous stem cell transplant 1

Complete Dosing Schedule for DRd

Daratumumab Dosing (16 mg/kg IV based on actual body weight):

• Weeks 1-8: Weekly (total 8 doses)
• Weeks 9-24: Every 2 weeks (total 8 doses)
• Week 25 onward: Every 4 weeks until disease progression

Lenalidomide Dosing:

• 25 mg orally days 1-21 of each 28-day cycle

Dexamethasone Dosing:

• 40 mg orally weekly (days 1,8,15,22 of each 28-day cycle)

5, 1

Alternative Daratumumab-Based Triplet: DVd

For patients with contraindications to lenalidomide or those who are lenalidomide-refractory, daratumumab-bortezomib-dexamethasone (DVd) is the alternative daratumumab-based triplet:

DVd Dosing:

• Daratumumab: 16 mg/kg IV weekly (cycles 1-3), every 3 weeks (cycles 4-8), every 4 weeks (cycles 9+)
• Bortezomib: 1.3 mg/m² subcutaneously days 1,4,8,11 (cycles 1-8 only)
• Dexamethasone: 20 mg orally days 1,2,4,5,8,9,11,12 (cycles 1-8)
• Cycles 1-8: 21-day cycles
• Cycles 9+: 28-day cycles

5, 1

Clinical Context and Supporting Evidence

Real-world data demonstrates excellent outcomes with first-line daratumumab use:

• A 2021 US chart review showed 100% overall response rate when daratumumab was initiated in first-line, compared to 78.8% in second-line and 65.2% in third-line or later 6
• 12-month progression-free survival rates were 89.9% for first-line daratumumab versus 75.2% for second-line and 53.1% for third-line or later 6

Meta-analysis data confirms superiority of daratumumab-containing quadruplets over triplets (pooled HR for PFS = 0.45,95% CI: 0.39-0.52), though the question specifically asks for triplet regimens 7

Important Clinical Considerations

Pre-medication Requirements:

• Corticosteroids, antipyretics, and antihistamines must be administered before each daratumumab infusion 1
• Type and screen patients prior to starting due to interference with blood bank testing 1

Monitoring:

• Complete blood counts periodically for neutropenia and thrombocytopenia 1
• Herpes zoster prophylaxis recommended with proteasome inhibitor-containing regimens 8
• Thromboprophylaxis: Full-dose aspirin or therapeutic anticoagulation for high-risk patients receiving immunomodulatory drugs 8

Common Toxicities:

• Infusion-related reactions (primarily with first infusion, manageable with pre-medication)
• Hematologic: Lymphopenia (87.5%), thrombocytopenia (52.8%), neutropenia 9
• Infections: Upper respiratory tract infections, pneumonia 1, 9

Duration of Therapy:

Continue treatment until disease progression or unacceptable toxicity 3. The guidelines support continuous therapy rather than fixed-duration treatment in the absence of MRD-guided strategies.

Pitfalls to Avoid

1. Do not delay daratumumab to later lines - efficacy decreases substantially with each subsequent line of therapy 6
2. Ensure proper infusion rate escalation - start conservatively and escalate only in absence of infusion reactions 1
3. Notify blood banks - daratumumab interferes with antibody screening; type and screen before starting therapy 1
4. Subcutaneous bortezomib preferred in DVd regimen to minimize peripheral neuropathy risk 5